再灌流の最適化による転帰と神経機能の改善

基本情報

NCT ID

NCT06990867

ステータス

募集中

試験のフェーズ

第2/第3相

試験タイプ

介入

目標被験者数

740

治験依頼者名

Corxel Pharmaceuticals

概要

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)